Search Results

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.

Zymeworks Inc. announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024.

Zymeworks Inc. announced that the United States Food and Drug Administration has cleared the investigational new drug application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin -expressing cancers.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that the Center for Drug Evaluation of the National Medical Products Administration in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.

Zymeworks Inc. announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.

Zymeworks Inc. today announced significant additions to its leadership team.